The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and When will the FDA reclassify BPC 157 to Category 1? Odds & Predictions